[Results of hyperfractionated radiation therapy used in combination with lomustin in malignant gliomas of the brain].
The postoperative use of lomustin, a nitrosourea agent, was investigated for its impact on the efficiency of hyperfractionated radiation therapy performed in patients with glioblastoma and anaplastic astrocytoma of the brain. A total of 35 patients (26 and 9 patients with glioblastoma and anaplastic astrocytoma, respectively) were followed up. Radiation therapy was performed, by using a total focal dose of 65 Gy in 2 steps or a single dose of 1.25 Gy twice daily every 4-6 hours. The patients received lomustin in a single oral dose of 160-200 mg at each of 2 stages of a hyperfractionated course of radiation therapy. The interval between two successive administrations was 5 weeks. Lomustin in combination with hyperfractionated radiation therapy was found to have no effect on the survival of patients with glioblastoma and anaplastic astrocytoma.